Product details
Liraglutide is a 31-amino-acid GLP-1 receptor agonist and the molecule that first established the fatty-acid-lipidation half-life strategy later carried through to Semaglutide and Tirzepatide. The structure pairs a C16 palmitoyl moiety, attached through a γ-glutamyl spacer at Lys26, with an Arg34-for-Lys34 substitution that blocks off-target acylation during synthesis; the C16 chain is the shorter end of the lipidation series the GLP-1 class is built on, which is why Liraglutide is a frequent comparator in incretin structure-activity studies. It is the active ingredient of approved finished drugs under separate brand names, but the material supplied here is a reference reagent only — characterized as a standard, not described for any therapeutic outcome.
Peptuno characterizes each Liraglutide lot as an analytical reference standard. Every vial carries its own data packet: RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity within 0.5 Da of the theoretical 3751.20 g/mol, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer. Because the 31-residue lipidated backbone sits at the more demanding end of routine SPPS, deletion sequences elute close to the target peak on RP-HPLC, so tandem-MS sequence verification is the recommended first-time-qualification test. Bacterial endotoxin (LAL) is an on-request add-on for in vivo metabolic-model work. Fills run mg-scale for reproducible aliquoting across a study series; this is reference-grade research material, distinct from compounding-scale API supply.
Regulatory note: Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations. Not a finished dosage form and not labelled for human administration. Liraglutide is the active ingredient of approved finished drugs under separate brand names, but the bulk active supplied here is a research reagent; buyers are responsible for institutional biosafety review and verifying import eligibility in the destination market.
FAQ
- What are Liraglutide's reference identity values (CAS, formula, MW)?
- Liraglutide CAS is 204656-20-2; molecular formula C172H265N43O51; average molecular weight 3751.20 g/mol. It is a 31-amino-acid GLP-1 receptor agonist carrying a C16 palmitoyl group on Lys26 via a γ-glutamyl spacer, with an Arg34 substitution. Each Peptuno lot confirms identity by ESI-MS within 0.5 Da of the theoretical mass and reproduces the value on the batch COA so it can be cited directly in a methods section.
- How does Liraglutide sit relative to Semaglutide and Tirzepatide as a reference series?
- All three use fatty-acid conjugation to extend half-life, but with increasing chain length and linker complexity: Liraglutide (C16, single γGlu spacer), Semaglutide (C18 diacid, extended linker), Tirzepatide (C20 diacid). Liraglutide is the shortest-acting and earliest member, which makes it the baseline anchor when the class is studied as a structure-activity progression. Peptuno supplies each as an independently characterized lot so a lab can confirm every member against its own analytical packet before comparison.
- What identity testing should a lab request when qualifying Liraglutide from a new source?
- Request the tandem-MS (LC-MS/MS) sequence-verification result on the first lot alongside RP-HPLC purity and ESI-MS intact mass. The lipidation modification at Lys26 shifts the mass roughly +396 Da relative to unmodified GLP-1(7-37); if the dominant species sits at the unmodified mass, the acylation step has not gone to completion. The b/y-ion ladder from LC-MS/MS demonstrates the supplied sequence matches the labelled sequence, and for in vivo metabolic-model work bacterial endotoxin (LAL) on the specific lot is the additional recommended test.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.